[HTML][HTML] SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …
and are especially important in high-risk individuals where vaccination is not an option …
[HTML][HTML] The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - academic.oup.com
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
SARS‐CoV‐2 variants and vulnerability at the global level
Numerous variants of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
pandemic have evolved. Viral variants may evolve with harmful susceptibility to the immunity …
pandemic have evolved. Viral variants may evolve with harmful susceptibility to the immunity …
[HTML][HTML] SARS-CoV-2 omicron variant: epidemiological features, biological characteristics, and clinical significance
Y Guo, J Han, Y Zhang, J He, W Yu, X Zhang… - Frontiers in …, 2022 - frontiersin.org
The SARS-CoV-2 Omicron (B. 1.1529) variant was designated as a variant of concern (VOC)
by the World Health Organization (WHO) on November 26, 2021. Within two months, it had …
by the World Health Organization (WHO) on November 26, 2021. Within two months, it had …
[PDF][PDF] TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry
J Baggen, M Jacquemyn, L Persoons, E Vanstreels… - Cell, 2023 - cell.com
SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by
the availability of entry receptors on host cells. Here, we show that TMEM106B, a lysosomal …
the availability of entry receptors on host cells. Here, we show that TMEM106B, a lysosomal …
Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir
The US FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …
[HTML][HTML] Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …
[HTML][HTML] Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
J Liu, X Pan, S Zhang, M Li, K Ma, C Fan… - The Lancet Regional …, 2023 - thelancet.com
Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …
Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial
Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed
to treat COVID-19. Evidence-based data to recommend either for or against the use of …
to treat COVID-19. Evidence-based data to recommend either for or against the use of …